{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:30:44Z","timestamp":1772166644998,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J of Biol Res-Thessaloniki"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Novel Coronavirus disease 2019 or COVID-19 has become a threat to human society due to fast spreading and increasing mortality. It uses vertebrate hosts and presently deploys humans. Life cycle and pathogenicity of SARS-CoV-2 have already been deciphered and possible drug target trials are on the way.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The present study was aimed to analyze Non-Structural Proteins that include conserved enzymes of SARS-CoV-2 like papain-like protease, main protease, Replicase, RNA-dependent RNA polymerase, methyltransferase, helicase, exoribonuclease and endoribonucleaseas targets to all known drugs. A bioinformatic based web server Drug ReposeER predicted several drug binding motifs in these analyzed proteins. Results revealed that anti-viral drugs Darunavir,Amprenavir, Rimantadine and Saquinavir were the most potent to have 3D-drug binding motifs that were closely associated with the active sites of the SARS-CoV-2 enzymes .<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\u00a0Repurposing of the antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir to treat COVID-19 patients could be useful that can potentially prevent human mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s40709-021-00149-2","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T22:02:44Z","timestamp":1628028164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins"],"prefix":"10.1186","volume":"28","author":[{"given":"Umesh C.","family":"Halder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"149_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","volume":"397","author":"MD Knoll","year":"2021","unstructured":"Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397:72\u20134.","journal-title":"Lancet"},{"key":"149_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim Results of a Phase 1\u20132a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021;384:1824\u201335.","journal-title":"N Engl J Med"},{"key":"149_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403\u201316.","journal-title":"N Engl J Med"},{"key":"149_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"149_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","volume":"5","author":"Y Dong","year":"2020","unstructured":"Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5:237.","journal-title":"Signal Transduct Target Ther"},{"key":"149_CR6","doi-asserted-by":"publisher","first-page":"101989","DOI":"10.1016\/j.tmaid.2021.101989","volume":"40","author":"R Sah","year":"2021","unstructured":"Sah R, Shrestha S, Mehta R, Sah SK, Rabaan AA, Dhama K, et al. AZD1222 (Covishield) vaccination for COVID-19: experiences, challenges, and solutions in Nepal. Travel Med Infect Dis. 2021;40:101989.","journal-title":"Travel Med Infect Dis"},{"key":"149_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jmv.25681","volume":"92","author":"Y Chen","year":"2020","unstructured":"Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418\u201323.","journal-title":"J Med Virol"},{"key":"149_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"AR Fehr","year":"2015","unstructured":"Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1\u201323.","journal-title":"Methods Mol Biol"},{"key":"149_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14:58\u201360.","journal-title":"Drug Discov Ther"},{"key":"149_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269\u201371.","journal-title":"Cell Res"},{"key":"149_CR11","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787\u201399.","journal-title":"N Engl J Med"},{"key":"149_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s10930-020-09901-4","volume":"39","author":"FK Yoshimoto","year":"2020","unstructured":"Yoshimoto FK. The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19. Protein J. 2020;39:198\u2013216.","journal-title":"Protein J"},{"key":"149_CR13","doi-asserted-by":"publisher","first-page":"605236","DOI":"10.3389\/fmolb.2020.605236","volume":"7","author":"G Mariano","year":"2020","unstructured":"Mariano G, Farthing RJ, Lale-Farjat SLM, Bergeron JRC. Structural characterization of SARS-CoV-2: where we are, and where we need to be. Front Mol Biosci. 2020;7:605236.","journal-title":"Front Mol Biosci"},{"key":"149_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe7386","author":"K Zhang","year":"2021","unstructured":"Zhang K, Miorin L, Makio T, Dehghan I, Gao S, Xie Y, et al. Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.abe7386.","journal-title":"Sci Adv"},{"key":"149_CR15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41594-020-0511-8","volume":"27","author":"K Schubert","year":"2020","unstructured":"Schubert K, Karousis ED, Jomaa A, Scaiola A, Echeverria B, Gurzeler LA, et al. SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. Nat Struct Mol Biol. 2020;27:959\u201366.","journal-title":"Nat Struct Mol Biol"},{"key":"149_CR16","doi-asserted-by":"publisher","first-page":"587317","DOI":"10.3389\/fmicb.2020.587317","volume":"11","author":"Y-Q Min","year":"2020","unstructured":"Min Y-Q, Mo Q, Wang J, Deng F, Wang H, Ning Y-J. SARS-CoV-2 nsp1: bioinformatics, potential structural and functional features, and implications for drug\/vaccine designs. Front Microbiol. 2020;11:587317.","journal-title":"Front Microbiol"},{"key":"149_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","volume":"584","author":"HS Hillen","year":"2020","unstructured":"Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P. Structure of replicating SARS-CoV-2 polymerase. Nature. 2020;584:154\u20136.","journal-title":"Nature"},{"key":"149_CR18","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/s41467-019-10280-3","volume":"10","author":"RN Kirchdoerfer","year":"2019","unstructured":"Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun. 2019;10:2342.","journal-title":"Nat Commun"},{"key":"149_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s43556-020-00005-0","volume":"1","author":"C Zhang","year":"2020","unstructured":"Zhang C, Chen Y, Li L. Structural basis for the multimerization of nonstructural protein nsp9 from SARS-CoV-2. Mol Biomed. 2020;1:5.","journal-title":"Mol Biomed"},{"key":"149_CR20","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41467-020-17495-9","volume":"11","author":"P Krafcikova","year":"2020","unstructured":"Krafcikova P, Silhan J, Nencka R, Boura E. Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin. Nat Commun. 2020;11:3717.","journal-title":"Nat Commun"},{"key":"149_CR21","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1038\/s41598-020-61432-1","volume":"10","author":"KJ Jang","year":"2020","unstructured":"Jang KJ, Jeong S, Kang DY, Sp N, Yang YM, Kim DE. A high ATP concentration enhances the cooperative translocation of the SARS coronavirus helicase nsP13 in the unwinding of duplex RNA. Sci Rep. 2020;10:4481.","journal-title":"Sci Rep"},{"key":"149_CR22","doi-asserted-by":"publisher","first-page":"e01246","DOI":"10.1128\/JVI.01246-20","volume":"94","author":"NS Ogando","year":"2020","unstructured":"Ogando NS, Zevenhoven-Dobbe JC, van der Meer Y, Bredenbeek PJ, Posthuma CC, Snijder EJ. The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2. J Virol. 2020;94:e01246-e1320.","journal-title":"J Virol"},{"key":"149_CR23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41467-020-20608-z","volume":"12","author":"MC Pillon","year":"2021","unstructured":"Pillon MC, Frazier MN, Dillard LB, Williams JG, Kocaman S, Krahn JM, et al. Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight into nuclease specificity and dynamics. Nat Commun. 2021;12:636.","journal-title":"Nat Commun"},{"key":"149_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41392-020-00241-4","volume":"5","author":"S Lin","year":"2020","unstructured":"Lin S, Chen H, Ye F, Chen Z, Yang F, Zheng Y, et al. Crystal structure of SARS-CoV-2 nsp10\/nsp16 2\u2032-O-methylase and its implication on antiviral drug design. Sig Transduct Target Ther. 2020;5:131.","journal-title":"Sig Transduct Target Ther"},{"key":"149_CR25","doi-asserted-by":"publisher","first-page":"101903","DOI":"10.1016\/j.isci.2020.101903","volume":"24","author":"C Semper","year":"2021","unstructured":"Semper C, Watanabe N, Savchenko A. Structural characterization of nonstructural protein 1 from SARS-CoV-2. IScience. 2021;24:101903.","journal-title":"IScience."},{"key":"149_CR26","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1021\/acs.biochem.0c00309","volume":"59","author":"DN Frick","year":"2020","unstructured":"Frick DN, Virdi RS, Vuksanovic N, Dahal N, Silvaggi NR. Molecular Basis for ADP-Ribose Binding to the Mac1 Domain of SARS-CoV-2 nsp3. Biochemistry. 2020;59:2608\u201315.","journal-title":"Biochemistry"},{"key":"149_CR27","doi-asserted-by":"crossref","unstructured":"Zhang B, Zhao Y, Jin Z, Liu X, Yang H, Rao Z. The crystal structure of COVID-19 main protease in apo form. PDB Data. 2020.","DOI":"10.2210\/pdb6m03\/pdb"},{"key":"149_CR28","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1093\/nar\/gkab370","volume":"49","author":"M Biswal","year":"2021","unstructured":"Biswal M, Diggs S, Xu D, Khudaverdyan N, Lu J, Fang J, et al. Two conserved oligomer interfaces of NSP7 and NSP8 underpin the dynamic assembly of SARS-CoV-2 RdRP. Nucleic Acids Res. 2021;49:5956\u201366.","journal-title":"Nucleic Acids Res"},{"key":"149_CR29","doi-asserted-by":"crossref","unstructured":"Tan K, Kim Y, Jedrzejczak R, Maltseva N, Endres M, Michalska K, et al. The crystal structure of Nsp9 RNA binding protein of SARS CoV-2. PDB Data. 2020.","DOI":"10.2210\/pdb6w4b\/pdb"},{"key":"149_CR30","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.3390\/ijms21197375","volume":"21","author":"A Rogstam","year":"2020","unstructured":"Rogstam A, Nyblom M, Christensen S, Sele C, Talibov VO, Lindvall T, et al. Crystal structure of non-structural protein 10 from severe acute respiratory syndrome coronavirus-2. Int J Mol Sci. 2020;21:7375.","journal-title":"Int J Mol Sci"},{"key":"149_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1126\/science.abb7498","volume":"368","author":"Y Gao","year":"2020","unstructured":"Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368:779\u201382.","journal-title":"Science"},{"key":"149_CR32","doi-asserted-by":"crossref","unstructured":"Newman JA,\u00a0YosaatmadjaY,\u00a0DouangamathA,\u00a0Bountra C,\u00a0Gileadi O. Crystal structure of the SARS-CoV-2 helicase APO form. PDB Data. 2021.","DOI":"10.2210\/pdb7nio\/pdb"},{"key":"149_CR33","doi-asserted-by":"publisher","first-page":"9436","DOI":"10.1073\/pnas.1508686112","volume":"112","author":"YY Ma","year":"2015","unstructured":"Ma YY, Wu LJ, Shaw N, Gao Y, Wang J, Sun YN, et al. Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc Natl Acad Sci U S A. 2015;112:9436\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"149_CR34","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/pro.3873","volume":"29","author":"Y Kim","year":"2020","unstructured":"Kim Y, Jedrzejczak R, Maltseva NI, Wilamowski M, Endres M, Godzik A, et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. Protein Sci. 2020;29:1596\u2013605.","journal-title":"Protein Sci"},{"key":"149_CR35","doi-asserted-by":"crossref","unstructured":"Yan LM,\u00a0Huang YC,\u00a0Lou ZY,\u00a0Rao ZH. Crystal structure of 2019-nCoV nsp16-nsp10 complex. PDB Data. 2020.","DOI":"10.2210\/pdb7bq7\/pdb"},{"key":"149_CR36","unstructured":"Drug ReposeER web server program. http:\/\/27.126.156.175\/drreposed\/. Accessed 25 Jun 2021."},{"key":"149_CR37","doi-asserted-by":"publisher","first-page":"W350","DOI":"10.1093\/nar\/gkz391","volume":"47","author":"NS Ab Ghani","year":"2019","unstructured":"Ab Ghani NS, Ramlan EI, Firdaus-Raih M. Drug ReposER: a web server for predicting similar amino acid arrangements to known drug binding interfaces for potential drug repositioning. Nucleic Acids Res. 2019;47:W350\u20136.","journal-title":"Nucleic Acids Res"},{"key":"149_CR38","first-page":"105","volume":"19","author":"J Mallolas","year":"2017","unstructured":"Mallolas J. Darunavir stands up as preferred HIV protease inhibitor. AIDS Rev. 2017;19:105\u201312.","journal-title":"AIDS Rev"},{"key":"149_CR39","doi-asserted-by":"publisher","first-page":"10438","DOI":"10.1038\/s41598-018-28638-w","volume":"8","author":"J Humpol\u00ed\u010dkov\u00e1","year":"2018","unstructured":"Humpol\u00ed\u010dkov\u00e1 J, Weber J, Starkov\u00e1 J, Ma\u0161\u00ednov\u00e1 E, G\u00fcnterov\u00e1 J, Flaisigov\u00e1 I, et al. Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation. Sci Rep. 2018;8:10438.","journal-title":"Sci Rep"},{"key":"149_CR40","doi-asserted-by":"publisher","first-page":"10517","DOI":"10.1038\/srep10517","volume":"5","author":"Y Yu","year":"2015","unstructured":"Yu Y, Wang J, Shao Q, Shi J, Zhu W. Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir. Sci Rep. 2015;5:10517.","journal-title":"Sci Rep"},{"key":"149_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/v9100277","volume":"9","author":"A Borrajo","year":"2017","unstructured":"Borrajo A, Ranazzi A, Pollicita M, Bruno R, Modesti A, Alteri C, et al. Effects of amprenavir on HIV-1 maturation, production and infectivity following drug withdrawal in chronically-infected monocytes\/macrophages. Viruses. 2017;9:277.","journal-title":"Viruses"},{"key":"149_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001169.pub3","author":"T Jefferson","year":"2006","unstructured":"Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev. 2006. https:\/\/doi.org\/10.1002\/14651858.CD001169.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"149_CR43","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1128\/AAC.48.12.4855-4863.2004","volume":"48","author":"EA Govorkova","year":"2004","unstructured":"Govorkova EA, Fang HB, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother. 2004;48:4855\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"149_CR44","doi-asserted-by":"publisher","first-page":"17425","DOI":"10.1021\/jacs.0c06419","volume":"142","author":"LC Watkins","year":"2020","unstructured":"Watkins LC, DeGrado WF, Voth GA. Influenza A M2 inhibitor binding understood through mechanisms of excess proton stabilization and channel dynamics. J Am Chem Soc. 2020;142:17425\u201333.","journal-title":"J Am Chem Soc"},{"key":"149_CR45","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jmgm.2007.04.009","volume":"26","author":"S Saen-oon","year":"2007","unstructured":"Saen-oon S, Aruksakunwong O, Wittayanarakul K, Sompornpisut P, Hannongbua S. Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V\/L90M mutants based on QM and QM\/MM calculations. J Mol Graph Model. 2007;26:720\u20137.","journal-title":"J Mol Graph Model"},{"key":"149_CR46","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/ci049784g","volume":"45","author":"K Wittayanarakul","year":"2005","unstructured":"Wittayanarakul K, Aruksakunwong O, Sompornpisut P, Sanghiran-Lee V, Parasuk V, Pinitglang S, et al. Structure, dynamics and solvation of HIV-1 protease\/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations. J Chem Inf Model. 2005;45:300\u20138.","journal-title":"J Chem Inf Model"},{"key":"149_CR47","doi-asserted-by":"publisher","first-page":"18555","DOI":"10.1038\/srep18555","volume":"5","author":"F Pietrucci","year":"2016","unstructured":"Pietrucci F, Vargiu A, Kranjc A. HIV-1 protease dimerization dynamics reveals a transient druggable binding pocket at the interface. Sci Rep. 2016;5:18555.","journal-title":"Sci Rep"},{"key":"149_CR48","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/v1031110","volume":"1","author":"IT Weber","year":"2009","unstructured":"Weber IT, Agniswamy J. HIV-1 protease: structural perspectives on drug resistance. Viruses. 2009;1:1110\u201336.","journal-title":"Viruses"},{"key":"149_CR49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.6026\/97320630004295","volume":"4","author":"S Shityakov","year":"2010","unstructured":"Shityakov S, Dandekar T. Lead expansion and virtual screening of Indinavir derivate HIV-1 protease inhibitors using pharmacophoric - shape similarity scoring function. Bioinformation. 2010;4:295\u20139.","journal-title":"Bioinformation"},{"key":"149_CR50","doi-asserted-by":"publisher","first-page":"104826","DOI":"10.1016\/j.phrs.2020.104826","volume":"157","author":"A Riva","year":"2020","unstructured":"Riva A, Conti F, Bernacchia D, Pezzati L, Sollima S, Merli S, et al. Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res. 2020;157:104826.","journal-title":"Pharmacol Res"},{"key":"149_CR51","doi-asserted-by":"publisher","first-page":"W315","DOI":"10.1093\/nar\/gkx337","volume":"45","author":"JPA Moraes","year":"2017","unstructured":"Moraes JPA, Pappa GL, Pires DEV, Izidoro SC. GASS-WEB: a web server for identifying enzyme active sites based on genetic algorithms. Nucleic Acids Res. 2017;45:W315\u20139.","journal-title":"Nucleic Acids Res"},{"key":"149_CR52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov. 2020;6:14.","journal-title":"Cell Discov"},{"key":"149_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2286-9","author":"DE Gordon","year":"2020","unstructured":"Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O\u2019Meara MJ, et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. bioRxiv. 2020. https:\/\/doi.org\/10.1038\/s41586-020-2286-9.","journal-title":"bioRxiv."},{"key":"149_CR54","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","volume":"18","author":"BR Beck","year":"2020","unstructured":"Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020;18:784\u201390.","journal-title":"Comput Struct Biotechnol J"},{"key":"149_CR55","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12093900.v1","author":"V Kouznetsova","year":"2020","unstructured":"Kouznetsova V, Huang D, Tsigelny IF. Potential COVID-19 protease inhibitors: repurposing FDA approved drugs. ChemRxiv. 2020. https:\/\/doi.org\/10.26434\/chemrxiv.12093900.v1.","journal-title":"ChemRxiv."},{"key":"149_CR56","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"C Wu","year":"2020","unstructured":"Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10:766\u201388.","journal-title":"Acta Pharm Sin B"},{"key":"149_CR57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"G Li","year":"2020","unstructured":"Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19:149\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"149_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00069-0","author":"P Olliaro","year":"2021","unstructured":"Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. Lancet Microbe. 2021. https:\/\/doi.org\/10.1016\/S2666-5247(21)00069-0.","journal-title":"Lancet Microbe"},{"issue":"4","key":"149_CR59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/vaccines9040341","volume":"9","author":"L Calzetta","year":"2021","unstructured":"Calzetta L, Ritondo BL, Coppola A, Matera MG, Di Daniele N, Rogliani P. Factors influencing the efficacy of COVID-19 vaccines: a quantitative synthesis of phase III trials. Vaccines (Basel). 2021;9(4):341.","journal-title":"Vaccines (Basel)"}],"container-title":["Journal of Biological Research-Thessaloniki"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40709-021-00149-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40709-021-00149-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40709-021-00149-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T23:26:48Z","timestamp":1628033208000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiolres.biomedcentral.com\/articles\/10.1186\/s40709-021-00149-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["149"],"URL":"https:\/\/doi.org\/10.1186\/s40709-021-00149-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-22247\/v1","asserted-by":"object"}]},"ISSN":["2241-5793"],"issn-type":[{"value":"2241-5793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]},"assertion":[{"value":"8 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}